Harnessing AI & ML for Drug Discovery: Revvity Signals’ Innovations

At a recent GEN event, The State of AI in Drug Discovery 2024, David Gosalvez, Head of Product Strategy at Revvity Signals, discusses how Revvity Signals software leverages Artificial Intelligence (AI) and Machine Learning (ML) to accelerate the discovery of therapeutic compounds, now and in the future.

The session explores the importance of AI/ML Ready Data with Signals Data Factory and showcase Large Language Models and Generative AI in Signals Notebook and Science Specific AI/ML Examples in Signals Research Suite, such as Chemical Reaction Recommendation Assistant and Antibody Developability Dashboard.

The drug discovery process is inherently complex, involving vast amounts of data and numerous intricate tasks. Revvity Signals recognizes the transformative potential of AI and ML in streamlining these processes and enhancing data analysis. By implementing these technologies, we aim to provide researchers with tools that reduce the time and effort spent on repetitive tasks, improve the quality of their work and allow them to focus on critical thinking and problem-solving. 

To listen to the entire GEN, The State of AI in Drug Discovery 2024 Virtual Summit click here.